Should a newly pregnant patient have a Pap smear at her first prenatal visit if she is up to date with prior screening?

Pap Smear During Pregnancy

Perform a Pap smear at the first prenatal visit ONLY if the newly pregnant patient is NOT up to date with cervical cancer screening according to standard guidelines.

Screening Approach in Pregnancy

The 2012 consensus guidelines from ACS, ASCCP, and ASCP (endorsed by NCCN) clearly state that pregnant women should follow the same cervical cancer screening intervals as non-pregnant women 1. This means:

• If the patient had appropriate screening within the recommended interval (cytology alone within 3 years, or cotesting within 5 years for women ≥30 years), do NOT repeat the Pap smear during pregnancy
• If the patient is overdue for screening, perform the Pap smear at the first prenatal visit as part of routine prenatal care

Key Rationale

The prevalence of abnormal Pap results in pregnancy does not differ from age-matched non-pregnant populations 2. Research demonstrates that:

• In patients without risk factors and a normal antepartum Pap smear, the prevalence of squamous intraepithelial lesions on postpartum smears is very low (4 in 1,000) 3
• A normal Pap smear during pregnancy does NOT need to be repeated postpartum—the next screening should follow standard yearly or longer intervals 3
• Cervical cytology is safe for both mother and fetus when performed correctly 4

Management Considerations

Conservative management is recommended for pregnant women with abnormal results 1:

• Pregnant women with CIN 3 can wait until after delivery for treatment
• Endocervical curettage is contraindicated in pregnancy
• Unless invasive cancer is detected, treatment should be deferred until after childbirth
• Only perform limited diagnostic excision if invasive cancer is suspected

Common Pitfall to Avoid

Do not perform unnecessary Pap smears in pregnancy simply because it's a "well-woman visit." Studies show that 67-94% of providers screen more frequently than recommended 5, contributing to $850 million in unnecessary cervical cancer screening costs annually. Pregnancy is not an indication to override evidence-based screening intervals.